Breaking News

0 294
Vermillion, Inc. VRML Stock News

Vermillion, Inc. (NASDAQ: VRML)

Vermillion is having an overwhelmingly strong day in the market today. In fact, when the trading session opened, the stock was already trading in the green. From there, it went on a tremendous spike upward before correcting and finding it’s support still well in the realm of gains. Below, we’ll talk about what we’re seeing from VRML, why, and what we’ll be watching for ahead.





What We’re Seeing From VRML

As mentioned above, Vermillion is having an overwhelmingly strong day in the market today. At the opening bell, the stock was already trading slightly in the green. However, that didn’t last long as slight gains became massive ones early on. Nonetheless, after hitting an early morning peak, the stock corrected before finding support, still with nice gains. Currently (12:25), VRML is trading at $2.07 per share after a gain of $0.32 per share or 18.03% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on VRML. As soon as we received the alert, the CNA Finance team went to work to figure out exactly what was causing the movement. It took some digging to find the story, but we believe we found the reason for the gains.




The gains seem to be the result of excitement surrounding an SEC filing. Through the filing, investors learned that insider, Larry N. Feinberg just made a large purchase of the stock. In fact, he purchased 617,731 shares in a transaction dated February 17th. The average cost of the purchase came to $1.40 per share, bringing the total value of the insider buy to $864,823.40.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on VRML. After all, when an insider makes a large purchase on a stock, it shows confidence and can sometimes be a clue of positive news to come. Nonetheless, we’ll keep a close eye on the news surrounding the stock and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 1166
Eyegate Pharmaceuticals Inc EYEG Stock News

EyeGate Pharmaceuticals Inc (NASDAQ: EYEG)

EyeGate Pharmaceuticals is having an overwhelmingly strong day in the market today. As soon as the market opened for the day, the stock was trading well into the green. Since then, we’ve seen some upward and some downward movement, but the stock has definitely been able to hold onto impressive gains. Below, we’ll talk about what we’re seeing from EYEG, why, and what we’ll be watching for ahead.





What We’re Seeing From EYEG

As mentioned above, EyeGate Pharmaceuticals is having an incredibly strong day in the market today. In fact, on the opening bell, the stock was trading well into the green. Since then, the stock has seen movement in both directions, but the gains are clearly here to stay. Currently (12:10), EYEG is trading at $2.47 per share after a gain of $0.84 per share (51.28%) thus far today.

Why The Stock Is Climbing

As is almost always the case, our partners at Trade Ideas were the first to notify us of the upward movement on EYEG. As soon as we received the alert, the CNA Finance team went to work to dig up the cause of the gains. It didn’t take long to find the story. Ultimately, the gains are the result of an announcement of a partnership that’s leading to quite a bit of investor excitement.




Early this morning, EyeGate Pharmaceuticals announced that it has partnered with Valeant Pharmaceuticals. The companies have entered into an exclusive, worldwide licensing agreement. Under the agreement, EYEG has granted a subsidiary of VRX exclusive, worldwide commercial and manufacturing rights to the EyeGate(R) II Delivery System as well as the EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on EYEG. In particular, we’ll be watching the relationship between the company and VRX as it evolves, as not only does this bring in some revenue now, but it could also be a major driver of future revenue. We’ll keep a close eye on the news and bring it to you as it breaks!

Update (1:14): EYEG continues to soar. In fact, if it keeps going at this rate, it could double by the closing bell. At the moment, the stock is trading at $2.83 per share after a gain of $1.19 per share (72.57%) thus far.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Popeyes Louisiana Kitchen Inc PLKI Stock News

Popeyes Louisiana Kitchen Inc (NASDAQ: PLKI)

Poppeyes Louisiana Kitchen is having an incredibly strong day in the market today. At the opening bell, the stock was already trading on overwhelmingly impressive gains. Since then, there has been no movement in either direction, but the gains are here to stay. Below, we’ll talk about what we’re seeing from PLKI, why, and what we’ll be watching for ahead.





What We’re Seeing From PLKI

As mentioned above, Popeyes Louisiana Kitchen is having a great day in the market today. At the opening bell, the stock was already trading cleanly in the green. Since the market open, we haven’t seen much by way of upward or downward movement as investors seem content with the current price. At the moment (11:58), PLKI is trading at $78.80 per share after a gain of $12.68 per share or 19.18% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to give us the alert that PLKI was up in a big way. As soon as we received the notification, the CNA Finance team started working to see what was causing the movement. It didn’t take long to dig up the story. The gains are the result of takeover news.




Recently we covered Popeyes Louisiana Kitchen as rumors started to break that the company was going to be acquired. However, this is unlike most other rumors. That’s because, this morning, the rumor became true. Restaurant Brands has agreed to buy Popeyes. The deal comes to a total of $1.8 billion in cash or $79 per share, representing a strong premium.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PLKI. In particular, we’ll be watching for further news surrounding this acquisition as it is subject to customary closing conditions. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 330
Momenta Pharmaceuticals, Inc. MNTA Stock News

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

Momenta Pharmaceuticals is having an incredibly rough day in the market today. As soon as the opening bell rang, the stock found itself deep in the red. Throughout the morning, we’ve seen some upward and some downward movement, but the losses seem to be here to stay. Below, we’ll talk about what we’re seeing from MNTA, why, and what we’ll be watching for ahead.





What We’re Seeing From MNTA

As mentioned above, Momenta Pharmaceuticals is having a pretty rough day in the market today. At the open of the trading session, the stock was already trading on dramatic losses. As the session progressed, we saw some upward and some downward movement, but the stock hasn’t been able to shake the big losses. At the moment (11:30), MNTA is trading at $15.96 per share after a loss of $3.04 per share or 16.03% thus far today.

Why The Stock Is Falling

As is almost always the case, our friends at Trade Ideas were the first to send the alert that MNTA was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to uncover the story, the declines seem to be the result of concerns surrounding an FDA warning letter.




Early this morning, Momenta Pharmaceuticals announced that Pfizer, the contracted fill/finish manufacturing partner focused on Sandoz has received an FDA warning letter. While the letter does not restrict the production or shipment of the Glatopa 20 mg product, it is proving to be a major concern to investors as the facility that received the warning is a key part of the supply chain. As a result, we’re seeing big declines.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MNTA. In particular, we’re watching for the company’s next steps as well as Pfizer’s response to the warning letter. Nonetheless, as always, we’ll keep a close eye on the news and be sure to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Legg Mason Inc LM Stock News

Legg Mason Inc (NYSE: LM)

Legg Mason was off to a pretty strong start to the trading session today. After starting the day off in the green, the stock went through a series of both ups and downs, but didn’t fall to the red at all. And minutes ago, things went from good to great as the stock started to make a run for the top. Below, we’ll talk about what we’re seeing from LM, why, and what we’ll be watching for ahead.





What We’re Seeing From LM

As mentioned above, Legg Mason had a pretty good start to the trading session today. After starting the day off in the green, the stock saw some normal upward and downward activity, but held onto the gains, for the most part. And then things went from good to great, minutes ago, as the stock started to make a run for the top. At the moment (11:07), LM is trading at $38.37 per share after a gain of $1.67 per share (4.55%) thus far today.

Why The Stock Is Spiking

As is usually the case, our friends at Trade Ideas were the first to alert us to the gains on LM. As soon as we go the alert, the CNA Finance team started working to see what was causing the gains. It didn’t take long to uncover the story in this case. The gains are ultimately the result of takeover chatter.




Minutes ago, Street Insider made an interesting report surrounding Legg Mason. The report was that the company has received a takeover offer. At this moment, we’re not quite sure who the offer came from or what the price on the offer was. Nonetheless, given the source of the news, we are comfortable saying that this is likely not a rumor.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on LM. In particular, we’ll be watching to see if the takeover offer does result in an acquisition. If it does, we can expect to see incredible value returned to shareholders. We’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 551
Cellect Biotechnology Ltd. APOP Stock News

Cellect Biotechnology Ltd. (NASDAQ: APOP)

Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we’ve seen a continuation of strong movement. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to APOP ahead.





What We’re Seeing From APOP

As mentioned above, Cellect Biotechnology is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. Throughout the morning, we’ve seen a continuation of gains. At the moment (10:52), APOP is trading at $6.91 per share after a gain of $1.08 per share (18.52%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to send the alert that APOP was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to uncover the story. The gains are ultimately the result of a positive data release.




Early this morning, Cellect Biotechnology released positive results from its clinical trial of ApoGraft(TM). The point of the study was to validate the company’s proprietary method for stem cell selection. To do so, the company went through the process of production and characterization through ApoGraft. In the announcement, investors learned that the company met its primary endpoint in this study.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on APOP. In particular, we’re following ongoing work with regard to ApoGraft as well as the rest of the company’s pipeline. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 1081
Trevena Inc TRVN Stock News

Trevena Inc (NASDAQ: TRVN)

Trevena is having an incredibly rough day in the market today, which is surprising to many considering that the company released data showing that it met its primary endpoint in recent clinical studies. Below, we’ll talk about what we’re seeing from TRVN, why, and what we’ll be watching for ahead.





What We’re Seeing From TRVN

As mentioned above, Trevena is having a rough day in the market today. At the opening bell, the stock was already trading well into the red, even though it released information saying that primary endpoints were met. Nonetheless, the stock continues to trade on overwhelming losses. Currently (10:29), TRVN is trading at $4.88 per share after a loss of $2.25 per share (31.56%) thus far today.

Why The Stock Is Falling

As is always the case, our partners at Trade Ideas were the first to send us the alert about the losses on TRVN today. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. At first, we were surprised to find that the company released positive data from clinical studies today. However, from there, it didn’t take long to find the declines.




The dramatic decline in the stock is the result of notes by Adam Feuerstein. Feuerstein pointed out several concerns associated with the announcement. Most importantly, some of the doses of oliceridine demonstrated lower rates of depressed breathing verses morphine and the only statistically significant observation was found in the lowest dose. He also pointed out that the improved tolerability was not deemed to be statistically significant.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TRVN. In particular, we’ll be watching the coming NDA to the FDA, and we’re interested in seeing if what Feuerstein pointed out becomes a hurdle to the process. We’ll continue to keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Aehr Test Systems AEHR Stock News

Aehr Test Systems (NASDAQ: AEHR)

Aehr Test Systems was off to what seemed to be a relatively normal day in the market today. When the opening bell rang, the stock was already trading slightly in the green. From there, it corrected a bit, traded flat, and then minutes ago, it spiked upward. Below, we’ll talk about what we’re seeing from AEHR, why, and what we’ll be watching for with regard to the stock ahead.





What We’re Seeing From AEHR

As mentioned above, Aehr Test Systems seemed like it was going to have a normal day in the market today. When the trading session opened for the day, the stock was already slightly in the green. From there, it fell slightly and traded relatively flat before spiking. At the moment (10:07), AEHR is trading at $4.77 per share after a gain of $0.66 per share or 16.06% thus far today.

Why The Stock Is Climbing

As is almost always the case, our partners at Trade Ideas were the first to notify us of the spike on AEHR. As soon as we got the alert, the CNA Finance team started working to see exactly what was causing the movement. It didn’t take very long to dig up the story. It seems as though the gains revolve around excitement caused by the announcement of a new order.




Minutes ago, Aehr Test Systems announced that it received yet another massive order. This time, the order was in excess of $4 million. The product that was ordered was the company’s Fox-XP(TM) Test and burn-in system with new singulated die/module test configuration. Of course, for a company of this size, a $4 million + order is massive!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AEHR. In particular, we are interested in watching the continued success of the company and we’ll be watching for more big sales like this one to be announced. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 294
Cidara Therapeutics Inc CDTX Stock News

Cidara Therapeutics Inc (NASDAQ: CDTX)

Cidara Therapeutics is having an overwhelmingly rough start to the trading session today, and for good reason. Unfortunately, the company reported results from a recent Phase 2 trial, and those results weren’t up to par. Below, we’ll talk about what we’re seeing from the stock, the results that were reported, and what we can expect from CDTX ahead.





What We’re Seeing From CDTX

As mentioned above, Cidara Therapeutics is having an incredibly disappointing start to the trading session today. When the opening bell rang, the stock was already trading incredibly low thanks to the early morning data release. Since the bell, the stock has maintained losses. At the moment (9:50), CDTX is trading at $7.25 per share after a loss of $4.45 per share or 38.08% thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to inform us of the declines on CDTX. As soon as we received the alert, the CNA Finance team started digging to see what was causing the movement. It didn’t take long to uncover the story. Unfortunately, the company missed the primary endpoint of a recent trial.




The trial was a controlled Phase 2 trial known as RADIANT During the trial Cidara Therapeutics was assessing the efficacy of echinocandin antifungal CD101 in women with moderate-to-severe acute VVC. Unfortunately, the efficacy trial showed that the treatment was not quite as effective as hoped. In a statement, Jeffrey Stein, Ph.D., President and CEO at CDTX, had the following to offer…

We are obviously disappointed with these results, which did not demonstrate the highly potent antifungal properties of CD101 against Candida we saw in preclinical animal models of VVC. While we believe that an improved topical formulation of CD101 could improve outcomes, at this time we have no plans for further development of CD101 topical in VVC…. We would like to thank the investigators and the patients who participated in this trial. This does not impact our development of CD101 IV for the treatment of Candidemia and invasive Candidiasis, for which animal models are well established and highly predictive of clinical outcomes.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CDTX. In particular, we’re interested in the company’s plans moving forward. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 2975
Peregrine Pharmaceuticals PPHM Stock News

Peregrine Pharmaceuticals (NASDAQ: PPHM)

Peregrine Pharmaceuticals is having an overwhelmingly strong day in the market today. When the trading session opened, the stock was already trading slightly in the green. However, as the trading session progressed, a good day quickly turned great. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to PPHM ahead.





What We’re Seeing From PPHM

As mentioned above, Peregrine Pharmaceuticals is having an incredibly strong day in the market today. After starting the session off slightly green, the stock quickly started to run for the top. After hitting a peak, it dipped a bit, but the gains are still incredible. At the moment (12:10), PPHM is trading at $0.60 per share after a gain of $0.16 per share (36.30%) thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the upward movement on PPHM. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, the gains are the result of a data release.




Early this morning, Peregrine Pharmaceuticals released encouraging data from a proof-of-concept study it has been working on. The study surrounds the company’s cancer detection platform that’s based on cell-derived vesicles known as exosomes.

From the data release, we learned that the PPHM test was able to distinguish between healthy subjects and patients that had ovarian tumors. This was seen through levels of exosomes in plasma samples that contained phosphatidylserine. Investigators also proved the ability to distinguish between benign and malignant tumors. This was done based on an analysis of PS-positive exosome levels.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance will be watching PPHM incredibly closely. In particular, we’ll be watching the company’s work toward pushing this test to commercial stages. We’ll continue to follow the story and bring the news to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

AzurRx BioPharma Inc. AZRX Stock News

0 744
AzurRx BioPharma Inc. (NASDAQ: AZRX) Since first covering AzurRx in December of 2016, many investors have asked me to further expand on the technology and...